Kardiorespirator tadqiqotlar jurnali 1 2021.pdf

Maqola mavzusi

YURAK ISHEMIK KASALLIGINI TEMIR TANQISLIK ANEMIYASI TURLI OG’IRLIK DARAJALARI FONIDA KECHISH XUSUSIYATLARI VA TUZALISH IMKONIYATLARI (44-46)

Mualliflar

Agababyan I.R., Ismoilova Y.A., Sadikova Sh.Sh.

Muassasa

SamDTI DKTF

Annotatsiya

Hozirgi vaqtda komorbidlik ya’ni bir yoki bir nechta kasalliklarni birgalikda kelishi dolzarb muammolardan biridir. Xususan biz yurak ishemik kasalligi (YUIK) stabil zo’riqish stenokardiya va anemiyaning turli og‘irlik darajalari haqida aytib o‘tamiz. Biz YUIK va turli og‘irlik darajasidagi anemiyasi bor bo‘lgan 30 ta bemorga 3 valentli temir preparati Sufer (Yuriya-farm Ukraina) 5 ml vena ichiga 5 kun mobaynida standart terapiya asosida quyamiz. Gemoglobin miqdorini normal ko‘rsatkichlarga kelishi, koronar qon tomirlarda qon aylanishni oshiradi va yurak mushaklarini kislorodga bo’lgan talabini qondiradi. Bu esa yurakni nasos sifatida samarali ishlashi uchun zarur bo‘lgan energiya muvozatini ta’minlaydi va jismoniy zo‘riqishlarga chidamlilikni oshiradi. Ayni paytda stabil zo’riqish stenokardiya va anemiyaning turli og‘irlikdagi darajalarini birgalikda kelishi komorbidlikni davolash va profilaktikasi dolzarb muammolardan biri hisoblanadi.YUIKni davolashda, aynan bizning hududda standart davolashga qo’shimcha ravishda unga hamroh bo‘lgan kasalliklarni davolash va muvozanatga keltirish ulkan natijalarni beradi

Kalit so'zlar

yurak ishemik kasalligi, temir tanqislik kamqonligi, 3 valentli temir preparati Sufer.

Adabiyotlar

1. Agababyan I.R.,Iskandarova F.I.,Axrorova Z.V.,Ismoilova Yu.A.Otsenka effektivnosti primeneniye preparata Sufer u patsiyentov s nestabilnoy stenokardiyey i jelezodefitsitnoy anemiyey.//Jurnal “Uzbekiston terapiya axborotnomasi”№3 Tashkent2018.S10. 2. IskandarovaF.I., AxrorovaZ.V., IsmoilovaYu.A.Primeneniye preparatov jeleza v kompleksnom lechenii bolnix nestabilnoy stenokardiyey i anemiyey.//Jurnal “Biologiya va tibbiyet muammolari”№1Samarkand 2019.S.145 3. Gorodetskiy V.V., Godulyan O.V. Jelezodefitsitnie sostoyaniya i jelezodefitsitnaya anemiya: diagnostika i lecheniye. // Metodicheskiye rekomendatsii. Medpraktika M Moskva 2004g. 4. Dvoretskiy L.I. Klinicheskiye rekomendatsii po lecheniyu bolnix jelezodefitsitnoy anemiyey. // Russkiy meditsinskiy jurnal. 2004, t. 12, №14, S. 893-897. 5.KarpovYu.A.,MerkulovaA.G.,XakimovA.G.,SamarenkoM.B.Sutochnoye monitorirovaniye.EKG u bolnix nestabilnoy stenokardiyey.//Kardiologiya.-2016.- №7.-S.67-72 6.KalyutaT.Yu. Klinika i prognoz pri ostrom infarkte miokarda i nestabilnoy stenokardii u bolnix s anemicheskim sindromom., Avtoref.diss.kand.med.nauk, 2004g. 7.StrenevF.V.Ob izmeneniyax serdsa,sentralnoy gemodinamiki i fizicheskoy rabotosposobnosti pod vliyaniyem jelezodefitsitnoy anemii legkoy i sredney stepeney tyajesti (kliniko-funksionalnoye issledovaniye):Avtoref. kand.med.naukStrenev F.V.- Sverdlovsk2009.S29. 8.Sudakov K.V.Funksionalnaya sistema, opredelyayushaya optimalniy uroven eritrotsitov v organizme.Klinicheskaya meditsina.//2002.№4.- S.4-11. 9.SurkinaI.D.,Stepura O.B.,Pak L.S.Immunointerferonovaya sistema i serdechno-sosudistie zabolevaniya.//Kardiologiya.-2005.-№4.-S.59-62. 10.Suxova N.D.,Belasheva I.I.,Puzirev V.P.Populyatsionno-geneticheskoye issledovaniye parametrov eritropoeza jelezodefitsitnix sostoyaniy u korennogo naseleniya Obskogo severa.//Lab.delo.-2016.-№4.-S.18-21. 11.Shilov A.M.,OsiyaA.O.Osobennosti lecheniya ishemicheskoy bolezni serdsa na fone anemii razlichnogo geneza.//Jurnal “Trudniy patsiyent”№12 Tom 9 Moskva 2011. S.10-14 12. Anker S.D., Sharma R., Frakis D. and al. Anemia and survival in 3044 patients with Chronic Heart Failure (CHF) in the ELITE II Study (abstract). Circulation. 2002; 106 9suppl.):233SA. 13. Felker G.M., Gattis W.A., Leimberger J.O. et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure // Am. J. Cardiol. 2003. – Vol. 92. – p. 625-628. 14.London G. Pathophysiology of cardiovascular damage in the early renal population. Nephrol Dial Transplant. 2001: 16 (suppl 2): 3-6.